Novo Nordisk (NVO.US): The upward revision of the performance outlook is mainly driven by increased sales expectations for GLP-1 products.

智通财经2026/08/04 16:45

Show original

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Nebius Q3 revenue reaches $980.8 million, exceeding expectations

智通财经•2026/11/12 12:32

JPMorgan lowers Nvidia's target price to $215

智通财经•2026/11/12 12:32

Melius Research downgrades Nvidia to 'Hold', lowers price target to $185

智通财经•2026/11/12 12:32

Argus Research lowers Reddit’s price target from $225 to $150

智通财经•2026/11/12 12:26